Polku Therapeutics

Polku Therapeutics is a Finnish biotechnology company focused on developing first-in-class, disease-modifying therapies for neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and other tauopathies. Spun out from the University of Helsinki, the company's proprietary platform targets the prolyl oligopeptidase (PREP) and protein phosphatase 2A (PP2A) pathway to restore cellular protein homeostasis, clear toxic tau and alpha-synuclein aggregates, and reduce neuroinflammation. Polku's lead preclinical candidate, POLK-38, is an orally administered small molecule that has demonstrated significant efficacy in reducing brain tau pathology and improving spatial learning in translational mouse models. Operating under a virtual drug development model, Polku leverages global resources and strategic partnerships to efficiently advance its portfolio of brain-penetrant small molecules toward clinical trials.